Zevra Therapeutics (ZVRA) Non Operating Income (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Non Operating Income data on file, last reported at -$7.3 million in Q1 2026.

• Quarterly Non Operating Income fell 313.12% year-over-year to -$7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138.8 million (up 4082.62% YoY) and the FY2025 annual result came in at $149.6 million, up 4869.56% from the prior year.
• Non Operating Income eased to -$7.3 million in Q1 2026, from $3.4 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $147.9 million in Q2 2025 to a low of -$7.3 million in Q1 2026.
• A 5-year average of $9.6 million and a median of $3.4 million in 2025 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2023 — Non Operating Income jumped 22595.65% — and 2026, when it sank 313.12%.
• Tracing ZVRA's Non Operating Income over 5 years: stood at $6.1 million in 2022, then tumbled by 177.45% to -$4.7 million in 2023, then declined by 4.58% to -$5.0 million in 2024, then surged by 167.67% to $3.4 million in 2025, then plunged by 319.1% to -$7.3 million in 2026.
• The last three Non Operating Income figures came in at -$7.3 million (Q1 2026), $3.4 million (Q4 2025), and -$5.1 million (Q3 2025), per Business Quant data.